GlassScriptPhysician profile
Kristi A Acker
NPI 1730413691
$3,116.73
in general payments reported to CMS, 2019-2025
39 companies · $794 in 2025
The $794 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $579 · 2022: $469 · 2023: $689 · 2024: $586 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $580.00 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $273.26 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $235.34 | 2021-2025 | Imfinzi, Calquence, Lynparza |
| Daiichi Sankyo INC. | $201.72 | 2021-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $155.24 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Seagen INC. | $138.85 | 2021-2023 | Padcev, Adcetris |
| Teva Pharmaceuticals USA, INC. | $112.33 | 2025 | Austedo Xr |
| Abbvie INC. | $97.95 | 2024-2025 | |
| Beone Medicines USA, INC. | $95.32 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $93.43 | 2021-2025 | Ojjaara |
| Eisai INC. | $86.36 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.75 | 2023 | Xifaxan |
| Astellas Pharma US INC | $84.89 | 2024-2025 | Xtandi |
| Beigene USA, INC. | $72.78 | 2023-2024 | Brukinsa |
| Novo Nordisk INC | $68.64 | 2023 | Wegovy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.